Τετάρτη 29 Νοεμβρίου 2017

[Review] De-novo and acquired resistance to immune checkpoint targeting

Use of immune checkpoint inhibitors targeting the programmed cell death protein-1/programmed cell death-ligand 1 and cytotoxic T lymphocyte-associated protein-4 axes has yielded impressive results in some clinical trials. However, only a subset of patients initially respond to these inhibitors, and increasing clinical evidence indicates that a substantial proportion of initial responders ultimately relapse with lethal, drug-resistant disease months or years later. Studies that have used massively parallel sequencing have shed light on the rich functional landscape of mutations that endow tumour cells with the ability to evade T-cell-mediated immunosurveillance.

http://ift.tt/2Agj4Uu

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου